Intentional coronary revascularization versus conservative therapy in patients after peripheral artery revascularization due to critical limb ischemia: the INCORPORATE trial.

Coronary angiography Coronary artery disease Critical limb ischemia Fractional flow reserve

Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
11 Jul 2024
Historique:
received: 08 04 2024
accepted: 25 06 2024
medline: 11 7 2024
pubmed: 11 7 2024
entrez: 11 7 2024
Statut: aheadofprint

Résumé

INCORPORATE trial was designed to evaluate whether default coronary-angiography (CA) and ischemia-targeted revascularization is superior compared to a conservative approach for patients with treated critical limb ischemia (CLI). Registered at clinicaltrials.gov (NCT03712644) on October 19, 2018. Severe peripheral artery disease is associated with increased cardiovascular risk and poor outcomes. INCORPORATE was an open-label, prospective 1:1 randomized multicentric trial that recruited patients who had undergone successful CLI treatment. Patients were randomized to either a conservative or invasive approach regarding potential coronary artery disease (CAD). The conservative group received optimal medical therapy alone, while the invasive group had routine CA and fractional flow reserve-guided revascularization. The primary endpoint was myocardial infarction (MI) and 12-month mortality. Due to COVID-19 pandemic burdens, recruitment was halted prematurely. One hundred eighty-five patients were enrolled. Baseline cardiac symptoms were scarce with 92% being asymptomatic. Eighty-nine patients were randomized to the invasive approach of whom 73 underwent CA. Thirty-four percent had functional single-vessel disease, 26% had functional multi-vessel disease, and 90% achieved complete revascularization. Conservative and invasive groups had similar incidences of death and MI at 1 year (11% vs 10%; hazard ratio 1.21 [0.49-2.98]). Major adverse cardiac and cerebrovascular events (MACCE) trended for hazard in the Conservative group (20 vs 10%; hazard ratio 1.94 [0.90-4.19]). In the per-protocol analysis, the primary endpoint remained insignificantly different (11% vs 7%; hazard ratio 2.01 [0.72-5.57]), but the conservative approach had a higher MACCE risk (20% vs 7%; hazard ratio 2.88 [1.24-6.68]). This trial found no significant difference in the primary endpoint but observed a trend of higher MACCE in the conservative arm.

Sections du résumé

OBJECTIVES OBJECTIVE
INCORPORATE trial was designed to evaluate whether default coronary-angiography (CA) and ischemia-targeted revascularization is superior compared to a conservative approach for patients with treated critical limb ischemia (CLI). Registered at clinicaltrials.gov (NCT03712644) on October 19, 2018.
BACKGROUND BACKGROUND
Severe peripheral artery disease is associated with increased cardiovascular risk and poor outcomes.
METHODS METHODS
INCORPORATE was an open-label, prospective 1:1 randomized multicentric trial that recruited patients who had undergone successful CLI treatment. Patients were randomized to either a conservative or invasive approach regarding potential coronary artery disease (CAD). The conservative group received optimal medical therapy alone, while the invasive group had routine CA and fractional flow reserve-guided revascularization. The primary endpoint was myocardial infarction (MI) and 12-month mortality.
RESULTS RESULTS
Due to COVID-19 pandemic burdens, recruitment was halted prematurely. One hundred eighty-five patients were enrolled. Baseline cardiac symptoms were scarce with 92% being asymptomatic. Eighty-nine patients were randomized to the invasive approach of whom 73 underwent CA. Thirty-four percent had functional single-vessel disease, 26% had functional multi-vessel disease, and 90% achieved complete revascularization. Conservative and invasive groups had similar incidences of death and MI at 1 year (11% vs 10%; hazard ratio 1.21 [0.49-2.98]). Major adverse cardiac and cerebrovascular events (MACCE) trended for hazard in the Conservative group (20 vs 10%; hazard ratio 1.94 [0.90-4.19]). In the per-protocol analysis, the primary endpoint remained insignificantly different (11% vs 7%; hazard ratio 2.01 [0.72-5.57]), but the conservative approach had a higher MACCE risk (20% vs 7%; hazard ratio 2.88 [1.24-6.68]).
CONCLUSION CONCLUSIONS
This trial found no significant difference in the primary endpoint but observed a trend of higher MACCE in the conservative arm.

Identifiants

pubmed: 38990250
doi: 10.1007/s00392-024-02487-2
pii: 10.1007/s00392-024-02487-2
doi:

Banques de données

ClinicalTrials.gov
['NCT03712644']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Teraa M, Conte MS, Moll FL, Verhaar MC (2016) Critical limb ischemia: current trends and future directions. J Am Heart Assoc 5. https://doi.org/10.1161/JAHA.115.002938
Adam DJ, Beard JD, Cleveland T et al (2005) Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 366:1925–1934. https://doi.org/10.1016/S0140-6736(05)67704-5
doi: 10.1016/S0140-6736(05)67704-5 pubmed: 16325694
Bradbury AW, Adam DJ, Bell J et al (2010) Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg 51:5S-17S. https://doi.org/10.1016/j.jvs.2010.01.073
doi: 10.1016/j.jvs.2010.01.073 pubmed: 20435258
Farooq V, Serruys PW, Bourantas C et al (2012) Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial. Eur Heart J 33:3105–3113. https://doi.org/10.1093/eurheartj/ehs367
doi: 10.1093/eurheartj/ehs367 pubmed: 23103663
Farooq V, van Klaveren D, Steyerberg EW et al (2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 381:639–650. https://doi.org/10.1016/S0140-6736(13)60108-7
doi: 10.1016/S0140-6736(13)60108-7 pubmed: 23439103
Toth G, Hamilos M, Pyxaras S et al (2014) Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. Eur Heart J 35:2831–2838. https://doi.org/10.1093/eurheartj/ehu094
doi: 10.1093/eurheartj/ehu094 pubmed: 24644308
Lee MS, Rha S-W, Han SK et al (2015) Clinical outcomes of patients with critical limb ischemia who undergo routine coronary angiography and subsequent percutaneous coronary intervention. J Invasive Cardiol 27:213–217
pubmed: 25840405
Neumann F-J, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40:87–165. https://doi.org/10.1093/eurheartj/ehy394
doi: 10.1093/eurheartj/ehy394 pubmed: 30165437
Mielniczuk LM, Toth GG, Xie JX et al (2017) Can functional testing for ischemia and viability guide revascularization? JACC Cardiovasc Imaging 10:354–364. https://doi.org/10.1016/j.jcmg.2016.12.011
doi: 10.1016/j.jcmg.2016.12.011 pubmed: 28279384
Toth G, Brodmann M, Barbato E et al (2019) Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial). Am Heart J 214:107–112. https://doi.org/10.1016/j.ahj.2019.05.005
doi: 10.1016/j.ahj.2019.05.005 pubmed: 31200280
Hardman R, Jazaeri O, Yi J et al (2014) Overview of classification systems in peripheral artery disease. Semin Intervent Radiol 31:378–388. https://doi.org/10.1055/s-0034-1393976
doi: 10.1055/s-0034-1393976 pubmed: 25435665 pmcid: 4232437
Perera D, Clayton T, O’Kane PD et al (2022) Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. https://doi.org/10.1056/NEJMoa2206606
doi: 10.1056/NEJMoa2206606 pubmed: 36322842
Al-Lamee R, Thompson D, Dehbi H-M et al (2018) Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. The Lancet 391:31–40. https://doi.org/10.1016/S0140-6736(17)32714-9
doi: 10.1016/S0140-6736(17)32714-9
Maron DJ, Hochman JS, Reynolds HR et al (2020) Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 382:1395–1407. https://doi.org/10.1056/NEJMoa1915922
doi: 10.1056/NEJMoa1915922 pubmed: 32227755 pmcid: 7263833
Xaplanteris P, Fournier S, Pijls NHJ et al (2018) Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med 379:250–259. https://doi.org/10.1056/NEJMoa1803538
doi: 10.1056/NEJMoa1803538 pubmed: 29785878
Zimmermann FM, Omerovic E, Fournier S et al (2019) Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J 40:180–186. https://doi.org/10.1093/eurheartj/ehy812
doi: 10.1093/eurheartj/ehy812 pubmed: 30596995
Dagenais GR, Lu J, Faxon DP et al (2013) Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease. J Am Coll Cardiol 61:702–711. https://doi.org/10.1016/j.jacc.2012.11.036
doi: 10.1016/j.jacc.2012.11.036 pubmed: 23410541 pmcid: 3701296
Poredoš P, Jug B (2007) The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 58:309–315. https://doi.org/10.1177/0003319707302494
doi: 10.1177/0003319707302494 pubmed: 17626985
Hiatt WR, Goldstone J, Smith SC et al (2008) Atherosclerotic peripheral vascular disease symposium II. Circulation 118:2826–2829. https://doi.org/10.1161/CIRCULATIONAHA.108.191171
doi: 10.1161/CIRCULATIONAHA.108.191171 pubmed: 19106403
Murabito JM, Evans JC, Nieto K et al (2002) Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 143:961–965. https://doi.org/10.1067/mhj.2002.122871
doi: 10.1067/mhj.2002.122871 pubmed: 12075249
Criqui MH, Langer RD, Fronek A et al (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381–386. https://doi.org/10.1056/NEJM199202063260605
doi: 10.1056/NEJM199202063260605 pubmed: 1729621
McKenna M, Wolfson S, Kuller L (1991) The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 87:119–128. https://doi.org/10.1016/0021-9150(91)90014-T
doi: 10.1016/0021-9150(91)90014-T pubmed: 1854359
Knuuti J, Ballo H, Juarez-Orozco LE et al (2018) The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 39:3322–3330. https://doi.org/10.1093/eurheartj/ehy267
doi: 10.1093/eurheartj/ehy267 pubmed: 29850808
Andreini D, Collet C, Leipsic J et al (2022) Pre-procedural planning of coronary revascularization by cardiac computed tomography: an expert consensus document of the Society of Cardiovascular Computed Tomography. EuroIntervention 18:e872–e887. https://doi.org/10.4244/EIJ-E-22-00036
doi: 10.4244/EIJ-E-22-00036 pubmed: 35994043 pmcid: 9743242
McFalls EO, Ward HB, Moritz TE et al (2004) Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 351:2795–2804. https://doi.org/10.1056/NEJMoa041905
doi: 10.1056/NEJMoa041905 pubmed: 15625331

Auteurs

Gabor G Toth (GG)

Department of Cardiology, University Heart Center Graz, Medical University Graz, Graz, Austria.

Marianne Brodmann (M)

Division of Angiology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

Sadeek S Kanoun Schnur (SS)

Department of Cardiology, University Heart Center Graz, Medical University Graz, Graz, Austria.
Department of Cardiology, Faculty of Medicine, Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary.
Royal Cornwall Hospitals NHS Trust, Truro, UK.

Stanislaw Bartus (S)

II Dept of Cardiology, Medical College, Jagiellonian University, Krakow, Poland.

Mislav Vrsalovic (M)

Department of Cardiology, University of Zagreb School of Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.

Oleg Krestianinov (O)

E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.

Petr Kala (P)

University Hospital Brno and Medical Faculty of Masaryk University, Brno, Czech Republic.

Jacek Bil (J)

Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland.

Robert Gil (R)

National Medical Institute of the Internal Affairs and Administration Ministry, Warsaw, Poland.

Jan Kanovsky (J)

University Hospital Brno and Medical Faculty of Masaryk University, Brno, Czech Republic.

Luigi Di Serafino (L)

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Luca Paolucci (L)

Department of Medicine and Surgery, Research Unit of Cardiovascular Science, Università Campus Bio-Medico Di Roma and Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.

Emanuele Barbato (E)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Fabio Mangiacapra (F)

Department of Medicine and Surgery, Research Unit of Cardiovascular Science, Università Campus Bio-Medico Di Roma and Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.

Zoltan Ruzsa (Z)

Department of Cardiology, Faculty of Medicine, Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary. zruzsa25@gmail.com.

Classifications MeSH